NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 45 filers reported holding NEUBASE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $28 | -22.2% | 150 | -19.8% | 0.00% | – |
Q4 2022 | $36 | – | 187 | +24.7% | 0.00% | – |
Q3 2022 | $0 | – | 150 | -35.1% | 0.00% | – |
Q2 2022 | $0 | -100.0% | 231 | -77.6% | 0.00% | – |
Q1 2022 | $2,000 | -92.3% | 1,029 | -89.1% | 0.00% | – |
Q4 2021 | $26,000 | -88.1% | 9,417 | -84.4% | 0.00% | – |
Q3 2021 | $218,000 | -62.0% | 60,230 | -49.7% | 0.00% | – |
Q2 2021 | $574,000 | +218.9% | 119,678 | +393.9% | 0.00% | – |
Q1 2021 | $180,000 | +11.8% | 24,231 | +5.8% | 0.00% | – |
Q4 2020 | $161,000 | +80.9% | 22,905 | +96.2% | 0.00% | – |
Q3 2020 | $89,000 | -32.6% | 11,672 | -22.3% | 0.00% | – |
Q2 2020 | $132,000 | +94.1% | 15,030 | +57.6% | 0.00% | – |
Q1 2020 | $68,000 | +21.4% | 9,537 | +22.3% | 0.00% | – |
Q4 2019 | $56,000 | +51.4% | 7,800 | +4.1% | 0.00% | – |
Q3 2019 | $37,000 | – | 7,490 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CARNEGIE MELLON UNIVERSITY | 939,412 | $371,000 | 0.21% |
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 470,524 | $186,000 | 0.20% |
CM Management, LLC | 450,000 | $178,000 | 0.20% |
Decheng Capital Management III (Cayman), LLC | 1,000,000 | $395,000 | 0.14% |
AIGH Capital Management LLC | 872,023 | $345,000 | 0.11% |
Greenlight Capital | 2,727,027 | $1,077,000 | 0.08% |
Worth Venture Partners, LLC | 212,035 | $84,000 | 0.05% |
PERKINS CAPITAL MANAGEMENT INC | 98,000 | $39,000 | 0.04% |
Sio Capital Management, LLC | 259,441 | $102,000 | 0.03% |
PRELUDE CAPITAL MANAGEMENT, LLC | 311,000 | $123,000 | 0.00% |